Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Function and CT Coronary Angiogram (CorCTCA) study

Novalia P Sidik, Margaret McEntegart, Giles Roditi, Thomas J Ford, Michael McDermott, Andrew Morrow, John Byrne, Jacqueline Adams, Allister Hargreaves, Keith G Oldroyd, David Stobo, Olivia Wu, Claudia-Martina Messow, Alex McConnachie, Colin Berry, Novalia P Sidik, Margaret McEntegart, Giles Roditi, Thomas J Ford, Michael McDermott, Andrew Morrow, John Byrne, Jacqueline Adams, Allister Hargreaves, Keith G Oldroyd, David Stobo, Olivia Wu, Claudia-Martina Messow, Alex McConnachie, Colin Berry

Abstract

Microvascular and/or vasospastic anginas are relevant causes of ischemia with no obstructive coronary artery disease (INOCA) in patients after computed tomography coronary angiography (CTCA).

Objectives: Our research has 2 objectives. The first is to undertake a diagnostic study, and the second is to undertake a nested, clinical trial of stratified medicine.

Design: A prospective, multicenter, randomized, blinded, sham-controlled trial of stratified medicine (NCT03477890) will be performed. All-comers referred for clinically indicated CTCA for investigation of suspected coronary artery disease (CAD) will be screened in 3 regional centers. Following informed consent, eligible patients with angina symptoms are enrolled before CTCA and remain eligible if CTCA excludes obstructive CAD. Diagnostic study: Invasive coronary angiography involving an interventional diagnostic procedure (IDP) to assess for disease endotypes: (1) angina due to obstructive CAD (fractional flow reserve ≤0.80); (2) microvascular angina (coronary flow reserve <2.0 and/or index of microvascular resistance >25); (3) microvascular angina due to small vessel spasm (acetylcholine); (4) vasospastic angina due to epicardial coronary spasm (acetylcholine); and (5) noncoronary etiology (normal coronary function). The IDP involves direct invasive measurements using a diagnostic coronary guidewire followed by provocation testing with intracoronary acetylcholine. The primary outcome of the diagnostic study is the reclassification of the initial CTCA diagnosis based on the IDP. Stratified medicine trial: Participants are immediately randomized 1:1 in the catheter laboratory to therapy stratified by endotype (intervention group) or not (control group). The primary outcome of the trial is the mean within-subject change in Seattle Angina Questionnaire score at 6 months. Secondary outcomes include safety, feasibility, diagnostic utility (impact on diagnosis and certainty), and clinical utility (impact on treatment and investigations). Health status assessments include quality of life, illness perception, anxiety-depression score, treatment satisfaction, and physical activity. Participants who are not randomized will enter a follow-up registry. Health and economic outcomes in the longer term will be assessed using electronic patient record linkage.

Value: CorCTCA will prospectively characterize the prevalence of disease endotypes in INOCA and determine the clinical value of stratified medicine in this population.

Conflict of interest statement

Disclosures Prof Colin Berry is employed by the University of Glasgow, which holds consultancy and research agreements with companies that have interests in the diagnosis and treatment of angina. The companies include Abbott Vascular, AstraZeneca, Boehringer Ingelheim, Coroventis, HeartFlow, and Siemens Healthcare. Prof Keith G. Oldroyd has received consultant and speaker fees from Abbott Vascular. Prof Olivia Wu holds consultancy agreement with Bayer and have received consultancy fees from Takeda and Lupin. None of these companies have had any involvement with this study. None of the other authors have any potential conflicts of interest. The authors are solely responsible for the design of this study, all study analyses, the drafting and editing of the paper, and its final contents.

Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Figures

Graphical abstract
Graphical abstract
Figure 1
Figure 1
Recruitment sites for CorCTCA. Three recruiting hospitals with a catchment area which covers West and Central Scotland (labeled in orange).
Figure 2
Figure 2
Schematic study design: flow diagram. ACh, acetylcholine.

References

    1. GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392(10159):1859–1922.
    1. Heart and circulatory disease statistics 2019: British Heart Foundation; 2019 April 2019.
    1. Knuuti J., Wijns W., Saraste A. ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2019:2019.
    1. Bairey Merz C.N., Pepine C.J., Walsh M.N. Ischemia and no obstructive coronary artery disease (INOCA): developing evidence-based therapies and research agenda for the next decade. Circulation. 2017;135(11):1075–1092.
    1. Ford T.J., Corcoran D., Berry C. Stable coronary syndromes: pathophysiology. diagnostic advances and therapeutic need Heart. 2018;104(4):284–292.
    1. Kaski J.C., Crea F., Gersh B.J. Reappraisal of ischemic heart disease. Circulation. 2018;138(14):1463–1480.
    1. Ford T.J., Rocchiccioli P., Good R. Systemic microvascular dysfunction in microvascular and vasospastic angina. Eur Heart J. 2018;39(46):4086–4097.
    1. ScotHeart Investigators CT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART): an open-label, parallel-group, multicentre trial. Lancet. 2015;385(9985):2383–2391.
    1. Ford T.J., Stanley B., Good R. Stratified medical therapy using invasive coronary function testing in angina: the CorMicA Trial. J Am Coll Cardiol. 2018;72(23 Pt A):2841–2855.
    1. Douglas P.S., Hoffmann U., Patel M.R. Outcomes of anatomical versus functional testing for coronary artery disease. N Engl J Med. 2015;372(14):1291–1300.
    1. Napp A.E., Haase R., Laule M. Computed tomography versus invasive coronary angiography: design and methods of the pragmatic randomised multicentre DISCHARGE trial. Eur Radiol. 2017;27(7):2957–2968.
    1. Dewey M., Rief M., Martus P. Evaluation of computed tomography in patients with atypical angina or chest pain clinically referred for invasive coronary angiography: randomised controlled trial. BMJ. 2016;i5441:355.
    1. Haase R., Schlattmann P., Gueret P. Diagnosis of obstructive coronary artery disease using computed tomography angiography in patients with stable chest pain depending on clinical probability and in clinically important subgroups: meta-analysis of individual patient data. BMJ. 2019;l1945:365.
    1. Skinner J.S., Smeeth L., Kendall J.M. Chest Pain Guideline Development G. NICE guidance. Chest pain of recent onset: assessment and diagnosis of recent onset chest pain or discomfort of suspected cardiac origin. Heart. 2010;96(12):974–978.
    1. Chest pain of recent onset: assessment and diagnosis (NICE guideline 95). In. - people-presenting-with-stable-chest-pain: National Institute for Health and Care Excellence; 2016.
    1. Management of stable angina (SIGN Guideline 151). In. Scottish Intercollegiate Guidelines Network; 2018.
    1. J. Knuuti, W. Wijns, A. Saraste, et al., 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes, Eur Heart J 2019;00:1-71.
    1. ScotHeart Investigators, Newby D.E., Adamson P.D. Coronary CT angiography and 5-year risk of myocardial infarction. N Engl J Med. 2018;379(10):924–933.
    1. Williams M.C., Hunter A., Shah A. Symptoms and quality of life in patients with suspected angina undergoing CT coronary angiography: a randomised controlled trial. Heart. 2017;103(13):995–1001.
    1. Ong P., Athanasiadis A., Borgulya G. High prevalence of a pathological response to acetylcholine testing in patients with stable angina pectoris and unobstructed coronary arteries. The ACOVA Study (Abnormal COronary VAsomotion in patients with stable angina and unobstructed coronary arteries) J Am Coll Cardiol. 2012;59(7):655–662.
    1. Sara J.D., Widmer R.J., Matsuzawa Y. Prevalence of coronary microvascular dysfunction among patients with chest pain and nonobstructive coronary artery disease. JACC Cardiovasc Interv. 2015;8(11):1445–1453.
    1. The Medical Research Council . UK: Medical Research Council (MRC) 2018. Framework for the development, design and analysis of stratified medicine research.
    1. Rose G., McCartney P., Reid D.D. Self-administration of a questionnaire on chest pain and intermittent claudication. Br J Prev Soc Med. 1977;31(1):42–48.
    1. Spertus J.A., Winder J.A., Dewhurst T.A. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol. 1995;25(2):333–341.
    1. Cury R.C., Abbara S., Achenbach S. CAD-RADS(TM) Coronary Artery Disease—Reporting and Data System. An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT), the American College of Radiology (ACR) and the North American Society for Cardiovascular Imaging (NASCI). Endorsed by the American College of Cardiology. J Cardiovasc Comput Tomogr. 2016;10(4):269–281.
    1. Ong P., Camici P.G., Beltrame J.F. International standardization of diagnostic criteria for microvascular angina. Int J Cardiol. 2018;250:16–20.
    1. Beltrame J.F., Crea F., Kaski J.C. International standardization of diagnostic criteria for vasospastic angina. Eur Heart J. 2017;38(33):2565–2568.
    1. Herdman M., Gudex C., Lloyd A. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) Qual Life Res. 2011;20(10):1727–1736.
    1. Janssen M.F., Pickard A.S., Golicki D. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2013;22(7):1717–1727.
    1. Broadbent E., Petrie K.J., Main J. The brief illness perception questionnaire. J Psychosom Res. 2006;60(6):631–637.
    1. Kroenke K., Spitzer R.L., Williams J.B. An ultra-brief screening scale for anxiety and depression: the PHQ-4. Psychosomatics. 2009;50(6):613–621.
    1. Bharmal M., Payne K., Atkinson M.J. Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes. 2009;7:36.
    1. von Elm E., Altman D.G., Egger M. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495–1499.
    1. Pancholy S.B., Sanghvi K.A., Patel T.M. Radial artery access technique evaluation trial: randomized comparison of Seldinger versus modified Seldinger technique for arterial access for transradial catheterization. Catheter Cardiovasc Interv. 2012;80(2):288–291.
    1. Bertrand O.F., Carey P.C., Gilchrist I.C. Allen or no Allen: that is the question! J Am Coll Cardiol. 2014;63(18):1842–1844.
    1. Lee J.M., Jung J.H., Hwang D. Coronary flow reserve and microcirculatory resistance in patients with intermediate coronary stenosis. J Am Coll Cardiol. 2016;67(10):1158–1169.
    1. Ford T.J., Berry C., De Bruyne B. Physiological predictors of acute coronary syndromes: emerging insights from the plaque to the vulnerable patient. JACC Cardiovasc Interv. 2017;10(24):2539–2547.
    1. Greenwood J.P., Ripley D.P., Berry C. Effect of care guided by cardiovascular magnetic resonance, myocardial perfusion scintigraphy, or NICE guidelines on subsequent unnecessary angiography rates: the CE-MARC 2 randomized clinical trial. JAMA. 2016;316(10):1051–1060.
    1. Corcoran D., Young R., Adlam D. Coronary microvascular dysfunction in patients with stable coronary artery disease: the CE-MARC 2 coronary physiology sub-study. Int J Cardiol. 2018;266:7–14.
    1. ISCHEMIA Trial Research Group Maron DJ, Hochman JS, O'Brien SM, Reynolds HR, Boden WE, et al. International study of comparative health effectiveness with medical and invasive approaches (ISCHEMIA) trial: rationale and design. Am Heart J. 2018;201:124–135.
    1. De Bruyne B., Fearon W.F., Pijls N.H. Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med. 2014;371(13):1208–1217.
    1. De Bruyne B., Pijls N.H., Kalesan B. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367(11):991–1001.
    1. Jespersen L., Hvelplund A., Abildstrom S.Z. Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. Eur Heart J. 2012;33(6):734–744.
    1. Douglas P.S., Pontone G., Hlatky M.A. Clinical outcomes of fractional flow reserve by computed tomographic angiography-guided diagnostic strategies vs. usual care in patients with suspected coronary artery disease: the prospective longitudinal trial of FFR(CT): outcome and resource impacts study. Eur Heart J. 2015;36(47):3359–3367.
    1. Berry C. Stable coronary syndromes: the case for consolidating the nomenclature of stable ischemic heart disease. Circulation. 2017;136(5):437–439.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅